title: Antitumour necrosis factor α treatment reduces retinol-binding protein 4 serum levels in non-diabetic ankylosing spondylitis patients.
authors: Epidemiology, Genetics and Atherosclerosis Research Group on Systemic Inflammatory Diseases, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, IFIMAV, Santander, Spain.
authors: Fernanda
authors: F
authors: Genre
authors: Raquel
authors: R
authors: López-Mejías
authors: José A
authors: JA
authors: Miranda-Filloy
authors: Begoña
authors: B
authors: Ubilla
authors: Beatriz
authors: B
authors: Carnero-López
authors: Inés
authors: I
authors: Gómez-Acebo
authors: Ricardo
authors: R
authors: Blanco
authors: Rodrigo
authors: R
authors: Ochoa
authors: Javier
authors: J
authors: Rueda-Gotor
authors: Trinitario
authors: T
authors: Pina
authors: Carlos
authors: C
authors: González-Juanatey
authors: Javier
authors: J
authors: Llorca
authors: Miguel A
authors: MA
authors: González-Gay
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D003920:Diabetes Mellitus; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D006801:Humans; D000069285:Infliximab; D008297:Male; D054839:Retinol-Binding Proteins, Plasma / Q000032:analysis*; D013167:Spondylitis, Ankylosing / Q000097:blood* / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
chemical_list: D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; C101326:RBP4 protein, human; D054839:Retinol-Binding Proteins, Plasma; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab
keywords: Ankylosing Spondylitis; Anti-TNF; Atherosclerosis; Inflammation